# Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

> **NCT05938075** · PHASE1 · COMPLETED · sponsor: **Vaccine Company, Inc.** · enrollment: 130 (actual)

## Conditions studied

- SARS-CoV
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** VXCO-100
- **BIOLOGICAL:** COVID-19 mRNA vaccine

## Key facts

- **NCT ID:** NCT05938075
- **Lead sponsor:** Vaccine Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-04
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938075, "Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05938075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*